S Nijim1, V Vujjini1, S Alasfar1, X Luo2, B Orandi2, C Delp2, N M Desai2, R A Montgomery3, B E Lonze2, N Alachkar4. 1. Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Surgery, New York University, New York, New York. 4. Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: nalachk1@jhmi.edu.
Abstract
BACKGROUND: Immunoglobulin (Ig)A nephropathy is the most common primary glomerulonephritis worldwide, with a high recurrence rate after kidney transplantation. The aim of this study was to assess allograft survival, impact of recurrence on allograft function, and risk factors for post-transplant IgA recurrence. METHODS: We identified 104 patients with IgA nephropathy who underwent kidney transplantation at our center between 1993 and 2014. Fourteen patients underwent more than one allograft. RESULTS: IgA recurrence was documented in 23 (19%) allografts. Median time to recurrence was 6.75 years (interquartile range, 1.4-9.2 years). Twelve of the 23 recurrences were from living related donors (P = .07), and those with younger age at transplantation (37.7 ± 2.3 vs 44 ± 1.3, P = .05) were at higher risk of recurrence. Mean allograft survival was reduced in those with recurrence (6.5 ± 5.1 years) compared with those without recurrence (10.4 ± 7.5 years). At 6 years after transplant, allograft failure was documented in 52% of the recurrence group compared with 10% in the non-recurrence group (P = .002). CONCLUSIONS: IgA recurrence after transplant is an important cause of allograft loss. Living related donors and younger age at transplantation are associated with high recurrence rate. Close monitoring and treatment of recurrence are crucial.
BACKGROUND: Immunoglobulin (Ig)A nephropathy is the most common primary glomerulonephritis worldwide, with a high recurrence rate after kidney transplantation. The aim of this study was to assess allograft survival, impact of recurrence on allograft function, and risk factors for post-transplant IgA recurrence. METHODS: We identified 104 patients with IgA nephropathy who underwent kidney transplantation at our center between 1993 and 2014. Fourteen patients underwent more than one allograft. RESULTS: IgA recurrence was documented in 23 (19%) allografts. Median time to recurrence was 6.75 years (interquartile range, 1.4-9.2 years). Twelve of the 23 recurrences were from living related donors (P = .07), and those with younger age at transplantation (37.7 ± 2.3 vs 44 ± 1.3, P = .05) were at higher risk of recurrence. Mean allograft survival was reduced in those with recurrence (6.5 ± 5.1 years) compared with those without recurrence (10.4 ± 7.5 years). At 6 years after transplant, allograft failure was documented in 52% of the recurrence group compared with 10% in the non-recurrence group (P = .002). CONCLUSIONS: IgA recurrence after transplant is an important cause of allograft loss. Living related donors and younger age at transplantation are associated with high recurrence rate. Close monitoring and treatment of recurrence are crucial.
Authors: Catherine R Kavanagh; Francesca Zanoni; Rita Leal; Namrata G Jain; Megan Nicole Stack; Elena-Rodica Vasilescu; Geo Serban; Carley Shaut; Jeanne Kamal; Satoru Kudose; António Martinho; Rui Alves; Dominick Santoriello; Pietro A Canetta; David Cohen; Jai Radhakrishnan; Gerald B Appel; Michael B Stokes; Glen S Markowitz; Vivette D D'Agati; Krzysztof Kiryluk; Nicole K Andeen; Ibrahim Batal Journal: Glomerular Dis Date: 2021-09-24
Authors: Anita Borski; Alexander Kainz; Nicolas Kozakowski; Heinz Regele; Johannes Kläger; Robert Strassl; Gottfried Fischer; Ingrid Faé; Sabine Wenda; Željko Kikić; Gregor Bond; Roman Reindl-Schwaighofer; Katharina A Mayer; Michael Eder; Markus Wahrmann; Susanne Haindl; Konstantin Doberer; Georg A Böhmig; Farsad Eskandary Journal: Front Med (Lausanne) Date: 2022-04-21
Authors: Audrey Uffing; Maria José Pérez-Saéz; Thomas Jouve; Mathilde Bugnazet; Paolo Malvezzi; Saif A Muhsin; Marie-Camille Lafargue; Roman Reindl-Schwaighofer; Alina Morlock; Rainer Oberbauer; Anna Buxeda; Carla Burballa; Julio Pascual; Seraina von Moos; Harald Seeger; Gaetano La Manna; Giorgia Comai; Claudia Bini; Luis Sanchez Russo; Samira Farouk; Pitchaphon Nissaisorakarn; Het Patel; Nikhil Agrawal; Gianna Mastroianni-Kirsztajn; Juliana Mansur; Hélio Tedesco-Silva; Carlucci Gualberto Ventura; Fabiana Agena; Elias David-Neto; Enver Akalin; Omar Alani; Marilda Mazzali; Roberto Ceratti Manfro; Andrea Carla Bauer; Aileen X Wang; Xingxing S Cheng; Jesse D Schold; Stefan P Berger; Paolo Cravedi; Leonardo V Riella Journal: Clin J Am Soc Nephrol Date: 2021-08 Impact factor: 10.614